These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16144804)

  • 1. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden.
    Goodyear O; Piper K; Khan N; Starczynski J; Mahendra P; Pratt G; Moss P
    Blood; 2005 Dec; 106(13):4217-24. PubMed ID: 16144804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Blockade Reinvigorates Bone Marrow CD8
    Kwon M; Kim CG; Lee H; Cho H; Kim Y; Lee EC; Choi SJ; Park J; Seo IH; Bogen B; Song IC; Jo DY; Kim JS; Park SH; Choi I; Choi YS; Shin EC
    Clin Cancer Res; 2020 Apr; 26(7):1644-1655. PubMed ID: 31941832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
    Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
    Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of CD8+ tumor infiltrating lymphocytes correlate with disease burden in bone marrow of therapy Naïve multiple myeloma patients.
    Hidalgo-Lopez JE; Higa MG; Ferrian S; Lin P; Blando J; Medeiros LJ; Bueso-Ramos CE
    Ann Diagn Pathol; 2019 Jun; 40():174-175. PubMed ID: 30509755
    [No Abstract]   [Full Text] [Related]  

  • 5. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.
    Walz S; Stickel JS; Kowalewski DJ; Schuster H; Weisel K; Backert L; Kahn S; Nelde A; Stroh T; Handel M; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S
    Blood; 2015 Sep; 126(10):1203-13. PubMed ID: 26138685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.
    Leone P; Berardi S; Frassanito MA; Ria R; De Re V; Cicco S; Battaglia S; Ditonno P; Dammacco F; Vacca A; Racanelli V
    Blood; 2015 Sep; 126(12):1443-51. PubMed ID: 26185130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.
    Choi C; Witzens M; Bucur M; Feuerer M; Sommerfeldt N; Trojan A; Ho A; Schirrmacher V; Goldschmidt H; Beckhove P
    Blood; 2005 Mar; 105(5):2132-4. PubMed ID: 15561890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.
    Witzens-Harig M; Hose D; Jünger S; Pfirschke C; Khandelwal N; Umansky L; Seckinger A; Conrad H; Brackertz B; Rème T; Gueckel B; Meißner T; Hundemer M; Ho AD; Rossi JF; Neben K; Bernhard H; Goldschmidt H; Klein B; Beckhove P
    Blood; 2013 May; 121(22):4493-503. PubMed ID: 23603913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.
    Spanoudakis E; Papoutselis M; Terpos E; Dimopoulos MA; Tsatalas C; Margaritis D; Rahemtulla A; Kotsianidis I; Karadimitris A
    Blood Cancer J; 2016 Nov; 6(11):e500. PubMed ID: 27834938
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
    Yousef S; Heise J; Lajmi N; Bartels K; Kröger N; Luetkens T; Atanackovic D
    J Transl Med; 2015 Jun; 13():197. PubMed ID: 26088750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
    Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
    Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
    Goodyear OC; Pratt G; McLarnon A; Cook M; Piper K; Moss P
    Blood; 2008 Oct; 112(8):3362-72. PubMed ID: 18658027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells Inhibit CD8+ T Cell Function in a Process that May Implicate Fibroblast Activation Protein α.
    Wang Y; Wu X; Hu Y
    Iran J Immunol; 2019 Dec; 16(4):278-290. PubMed ID: 31885005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
    Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
    Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
    Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
    Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
    Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
    Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
    Frassanito MA; Ruggieri S; Desantis V; Di Marzo L; Leone P; Racanelli V; Fumarulo R; Dammacco F; Vacca A
    Eur J Haematol; 2015 Jul; 95(1):65-74. PubMed ID: 25409753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.
    Botta C; Cuce M; Caracciolo D; Fiorillo L; Tagliaferri P; Tassone P
    Curr Cancer Drug Targets; 2017; 17(9):819-838. PubMed ID: 28359248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?
    Braga WM; da Silva BR; Alves VL; Bortoluzo AB; Atanackovic D; Colleoni GW
    Immunotherapy; 2014; 6(5):569-75. PubMed ID: 24896625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.